USFDA concludes inspection at Zydus’ LiqMeds in U.K. with four observations

Zydus Lifesciences announced on November 14, 2026, that the United States Food and Drug Administration (USFDA) has concluded an inspection of its LiqMeds facility in the United Kingdom. The inspection, which took place between November 9 and November 13, resulted in four observations.

In a regulatory filing, the Ahmedabad-based pharmaceutical company stated that it intends to work closely with the USFDA to address these observations expeditiously. This disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Zydus Lifesciences acquired the LiqMeds Group in October 2023 through its subsidiary, Zydus Pharmaceuticals U.K.